TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02953847

Intervention type: DRUG
Group type: OTHER
Intervention: Rifafour e-275
Description: Rifampicin/isoniazid/pyrazinamide/ethambutol 150/75/400/275 mg This 4-drug FDC is the most widely used 4-drug FDC in South Africa with an estimated 100% of the SA DOH tender.

Intervention type: DRUG
Group type: OTHER
Intervention: Rifafour e-275
Description: Rifampicin/isoniazid/pyrazinamide/ethambutol 150/75/400/275 mg This 4-drug FDC is the most widely used 4-drug FDC in South Africa with an estimated 100% of the SA DOH tender.

Intervention type: DRUG
Group type: OTHER
Intervention: Rifafour e-275
Description: Rifampicin/isoniazid/pyrazinamide/ethambutol 150/75/400/275 mg This 4-drug FDC is the most widely used 4-drug FDC in South Africa with an estimated 100% of the SA DOH tender.

Intervention type: DRUG
Group type: OTHER
Intervention: Rifafour e-275
Description: Rifampicin/isoniazid/pyrazinamide/ethambutol 150/75/400/275 mg This 4-drug FDC is the most widely used 4-drug FDC in South Africa with an estimated 100% of the SA DOH tender.

Intervention type: DRUG
Group type: OTHER
Intervention: Rifafour e-275
Description: Rifampicin/isoniazid/pyrazinamide/ethambutol 150/75/400/275 mg This 4-drug FDC is the most widely used 4-drug FDC in South Africa with an estimated 100% of the SA DOH tender.

Intervention type: DRUG
Group type: OTHER
Intervention: Rimactazid 150/75
Description: Rifampicin/isoniazid 150/75 mg This 2-drug FDC is one of 2 widely used 2-drug FDCs in South Africa, with an estimated 30% of the SA DOH tender. Rifinah® made by Sanofi-Aventis holds about 70% of the tender, however as the Sanofi-Aventis 4-drug FDC will also be evaluated.

Intervention type: DRUG
Group type: OTHER
Intervention: Rimactazid 150/75
Description: Rifampicin/isoniazid 150/75 mg This 2-drug FDC is one of 2 widely used 2-drug FDCs in South Africa, with an estimated 30% of the SA DOH tender. Rifinah® made by Sanofi-Aventis holds about 70% of the tender, however as the Sanofi-Aventis 4-drug FDC will also be evaluated.

Intervention type: DRUG
Group type: OTHER
Intervention: Rimactazid 150/75
Description: Rifampicin/isoniazid 150/75 mg This 2-drug FDC is one of 2 widely used 2-drug FDCs in South Africa, with an estimated 30% of the SA DOH tender. Rifinah® made by Sanofi-Aventis holds about 70% of the tender, however as the Sanofi-Aventis 4-drug FDC will also be evaluated.
Study: NCT01464827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir capsules
Study: NCT00661466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Collagen Sponge
Study: NCT02804087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MobiusHD
Description: The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Implantation
Description: Sham Implantation
Study: NCT03513406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Sugammadex is indicated for the reversal of neuromuscular blockade.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Neostigmine is indicated for the reversal of neuromuscular blockade.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: Glycopyrrolate is used in conjunction with neostigmine to prevent neostigmine's muscarinic effects.
Study: NCT04857203

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D
Description: Vitamin D levels will be measured for the patients undergoing neoadjuvant therapy in patients with locally advanced rectal cancer

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D
Description: Vitamin D levels will be measured for the patients undergoing neoadjuvant therapy in patients with locally advanced rectal cancer
Study: NCT05028426

Intervention type: PROCEDURE
Intervention: Enhanced recovery program
Description: Enhanced recovery programs are a multimodal approach to optimize patients' physiological and psychological states in the preoperative, intraoperative and postoperative care domains.

Intervention type: PROCEDURE
Intervention: Enhanced recovery program
Description: Enhanced recovery programs are a multimodal approach to optimize patients' physiological and psychological states in the preoperative, intraoperative and postoperative care domains.
Study: NCT00677235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLAIR Endovascular Stent Graft
Description: Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PTA
Description: Treatment of stenoses with PTA only
Study: NCT00122642

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alcohol-lock
Description: The intervention is the instillation of ethanol 70% solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo-lock
Description: The intervention is the instillation of placebo solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
Study: NCT00624481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: 20ug subcutaneous injection daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide Nasal Spray
Description: teriparatide intranasally daily for 24 weeks
Study: NCT02158117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nasal naloxone
Description: one puff in one nostril with the subject is lying down
Study: NCT00264420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: At baseline 4 mg IV zoledronic acid over 15 min. every 4 weeks for 6 months plus radiation therapy 30 Gy in 10 fractions (5 times per week for first two weeks)
Study: NCT00509834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hLF1-11
Description: The study treatment consists of IV administration of:~(A) hLF1-11 (0.5mg IV bolus daily for 14 days) + fluconazole (up to 1g IV four times daily; 14 days): Group #1, n=10; OR (B) Fluconazole (up to 1g IV four times daily; 14 days) + matching placebo for hLF1-11: Group #2, n=10
Study: NCT02953847

Intervention type: DRUG
Group type: OTHER
Intervention: Rimactazid 150/75
Description: Rifampicin/isoniazid 150/75 mg This 2-drug FDC is one of 2 widely used 2-drug FDCs in South Africa, with an estimated 30% of the SA DOH tender. Rifinah® made by Sanofi-Aventis holds about 70% of the tender, however as the Sanofi-Aventis 4-drug FDC will also be evaluated.
Study: NCT00509834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hLF1-11
Description: 0.5mg hLF1-11 iv per day for 14 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03258216

Intervention type: DIAGNOSTIC_TEST
Intervention: panendoscopy
Description: panendoscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: panendoscopy
Description: panendoscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: tongue image
Description: capture tongue images by Automatic Tongue Diagnosis System

Intervention type: DIAGNOSTIC_TEST
Intervention: tongue image
Description: capture tongue images by Automatic Tongue Diagnosis System
Study: NCT02365675

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cotton gauze with petrolatum

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cellulose acetate with petrolatum

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nanocrystalline silver (Acticoat)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carboxymethylcellulose with ionic silver (Aquacel Ag)
Study: NCT04227574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zero Time Exercise training + WhatsApp anti-inertia reminders
Description: Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.~In addition, WhatsApp anti-inertia reminders will be sent daily by the research assistant to remind and encourage the participants to practice the Zero Time Exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zero Time Exercise training alone
Description: Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
Study: NCT02529150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: This is an exercise intervention study. All 10 participants will complete 26 weeks high dose exercise (60% of peak aerobic capacity 45 min/session, 5 sessions per week).
Study: NCT03965156

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1) Ultrasound guided Erector spinae block
Description: In the lateral position, after skin sterilization, erector spinae plane block will be performed at the level of T9. Counting down from the spine of seventh cervical vertebrae, the spine of the nine thoracic vertebrae (T9). A linear low frequency ultrasound transducer (US) (3-5 MHz) will placed sagittal 3cm lateral to midline to visualize the muscles of the back, transverse process and simmering pleura in between transverse processes. A 22-gauge short bevel needle will be inserted in cranial-caudal direction towards transverse process (TP) in plane to the US transducer until needle touched the TP crossing all the muscles. The location of the needle tip will be confirmed by visible normal saline fluid separating erector spinae muscle off the bony shadow of the transverse process on ultrasound imaging. Then 20 ml of bupivacaine 0.375% plus plus 5ug/ml adrenaline (1:200000) will be injected. The procedure will be repeated following the same steps on the other side of the back.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided transversus abdominis plane block
Description: in supine position and after skin sterilization. The linear high frequency transducer (6-13 MHz) will be placed in the transverse plane to the the lateral abdominal wall in the midaxillary line, between the lower costal margin and iliac crest. The three abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) are visualized. The needle inserted in plane and advanced anterior to posterior under continual visualization until the tip between the internal oblique and the transversus abdominis muscle. After negative aspiration, a 20 ml of bupivacaine 0.375% plus 5ug/ml adrenaline (1:200000) will be injected. The success of the injection will be confirmed by separation of the internal oblique and transversus abdominis with a distinct pocket of local anesthetic in between. The procedure will be repeated following the same steps on the other side.
Study: NCT00325364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Insulin Inhalation Powder
Description: patient specific dose, inhaled, before meals, 24 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injectable insulin
Description: patient specific dose, injectable, before meals, 24 months
Study: NCT00118716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol
Description: Fluticasone propionate/salmeterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: Fluticasone Propionate
Study: NCT00661466

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT00274846

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: 10 million units three times a week for a total of 6 doses. For any subject less than 45 kilograms the IL-2 will be given at 5 million units per meter squared three times weekly for a total of 6 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: Cells infused per kg. 1.5-8.0 x 10\^7/kg Total cells infused(for 70 kg. adult) 1.05 - 5.6 x 10\^9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Days -5 and -4: 60 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Days -5 through -2: 25 mg/m\^2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro treated peripheral blood stem cell transplantation
Description: Day 0 infuse natural killer cells
Study: NCT02572999

Intervention type: PROCEDURE
Intervention: Not applicable (observational design)
Study: NCT01764152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nasopharyngeal sample
Description: The nasopharyngeal sample will be used to find the types and subtypes of influenza virus and other respiratory viruses.
Study: NCT03630458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pearl millet couscous - made in Senegal
Description: Pearl millet couscous (made in Senegal) was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pearl millet couscous - made in USA
Description: Pearl millet couscous (made in USA) was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
Study: NCT02787707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Persumac
Description: 2.7 grams Persumac powder (Iranian traditional medicine remedy composed from sumac and Bunium Persicum) every 8 hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lactose
Description: 2.7 grams Lactose every 8 hour
Study: NCT03630458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pearl millet thick porridge
Description: Pearl millet thick porridge was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheat couscous
Description: Wheat couscous was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
Study: NCT00624481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide Nasal Spray
Description: teriparatide intranasally daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide Nasal Spray
Description: teriparatide intranasally daily for 24 weeks
Study: NCT02953847

Intervention type: DRUG
Group type: OTHER
Intervention: Rimactazid 150/75
Description: Rifampicin/isoniazid 150/75 mg This 2-drug FDC is one of 2 widely used 2-drug FDCs in South Africa, with an estimated 30% of the SA DOH tender. Rifinah® made by Sanofi-Aventis holds about 70% of the tender, however as the Sanofi-Aventis 4-drug FDC will also be evaluated.

Intervention type: DRUG
Group type: OTHER
Intervention: Rimactazid 150/75
Description: Rifampicin/isoniazid 150/75 mg This 2-drug FDC is one of 2 widely used 2-drug FDCs in South Africa, with an estimated 30% of the SA DOH tender. Rifinah® made by Sanofi-Aventis holds about 70% of the tender, however as the Sanofi-Aventis 4-drug FDC will also be evaluated.
Study: NCT04662281

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: LX9211 matching-placebo, tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX9211
Description: LX9211, 200 mg, tablets will be administered orally.
Study: NCT04393480

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Robotic therapy
Description: ReoGo™ - Motorika robotic therapy - upper extremity robotic rehabilitation system

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional therapy
Description: Range of Motion (ROM) exercises, muscle strengthening, balance and mobility training, exercises for enhancing activities of daily life, neurophysiological exercises, turnings, bed movements, bridge building, sitting and transfer training, gait training, proprioceptive exercises, balance exercises on the balance board of those affected by the cerebellar system, occupational therapy, cognitive rehabilitation by the relevant psychologist given to those with cognitive impairment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Range of Motion (ROM) exercises, muscle strengthening, balance and mobility training, exercises for enhancing activities of daily life, neurophysiological exercises, turnings, bed movements, bridge building, sitting and transfer training, gait training, proprioceptive exercises, balance exercises on the balance board of those affected by the cerebellar system, occupational therapy, cognitive rehabilitation by the relevant psychologist given to those with cognitive impairment
Study: NCT01931943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selatinib ditosilate tablets
Study: NCT03606928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, oxaliplatin, 5-FU, leucovorin
Description: This is a single-arm study with all patients receiving mFLOT chemotherapy.
Study: NCT03055897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLux 2020 System
Description: Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
Study: NCT01176149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMBG plus intensive education
Study: NCT02792192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedule specified in respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedule specified in respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedule specified in respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedule specified in respective arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacille Calmette-Guérin
Description: For Cohort 1B, BCG will be administered (intravesically) at de-escalated doses. De-escalation will be allowed for up to three dose levels of BCG: full dose (50 mg), 66% of full dose, and 33% of full dose. After the MTD or MAD is determined for Cohort 1B, MTD/MAD will be used for all subsequent participants enrolled into Cohorts 1B, 2, and 3 (provided MAD or MTD is determined to be either full dose or 66% of a full BCG dose).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacille Calmette-Guérin
Description: For Cohort 1B, BCG will be administered (intravesically) at de-escalated doses. De-escalation will be allowed for up to three dose levels of BCG: full dose (50 mg), 66% of full dose, and 33% of full dose. After the MTD or MAD is determined for Cohort 1B, MTD/MAD will be used for all subsequent participants enrolled into Cohorts 1B, 2, and 3 (provided MAD or MTD is determined to be either full dose or 66% of a full BCG dose).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacille Calmette-Guérin
Description: For Cohort 1B, BCG will be administered (intravesically) at de-escalated doses. De-escalation will be allowed for up to three dose levels of BCG: full dose (50 mg), 66% of full dose, and 33% of full dose. After the MTD or MAD is determined for Cohort 1B, MTD/MAD will be used for all subsequent participants enrolled into Cohorts 1B, 2, and 3 (provided MAD or MTD is determined to be either full dose or 66% of a full BCG dose).
Study: NCT06284057

Intervention type: PROCEDURE
Intervention: Bifurcation PCI with two stent technique Culotte Technique or Double Kiss (DK) Culotte
Description: Patient with CAD and coexisting bifurcation lesion requiring two-stent approach treated with Culotte Technique or Double Kiss (DK) Culotte due to operator distraction.

Intervention type: PROCEDURE
Intervention: Bifurcation PCI with two stent technique Culotte Technique or Double Kiss (DK) Culotte
Description: Patient with CAD and coexisting bifurcation lesion requiring two-stent approach treated with Culotte Technique or Double Kiss (DK) Culotte due to operator distraction.
Study: NCT01461317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: Participants will receive etrolizumab at a dose of 100 mg.
Study: NCT03770039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral PF-06700841 containing 14C microtracer
Description: Oral dose of 60 mg unlabeled PF-06700841 co-formulated with 30 ug 14C-labeled (300 nCi) PF-06700841 in 1st period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral unlabeled PF-06700841
Description: 60 mg unlabeled PF-06700841 oral dose in 2nd period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV 14C-labeled PF-06700841
Description: 30 ug 14C-labeled (300 nCi) PF-06700841 intravenous infusion over 5 min in 2nd period
Study: NCT01092091

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Recombinant Human Arginase I
Description: Weekly dose of PEG-BCT-100 for at least 8 weeks (or until disease progression) at 1600U/kg
Study: NCT03429933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT01372488

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture self removal
Description: Suture self removal

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Suture removal by family doctor or clinic
Description: As above
Study: NCT04362696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High definition transcranial electrical current stimulation
Description: Low-intensity and safe, noninvasive application of electrical current to the human scalp with the goal of gradually modulating levels of neuronal excitability.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: High definition transcranial electrical current stimulation
Description: Low-intensity and safe, noninvasive application of electrical current to the human scalp with the goal of gradually modulating levels of neuronal excitability.